TYRA

Tyra Biosciences, Inc.

Healthcare
Biotechnology
$1.31B market cap

Forecast run · Sep 14, 2026Upside rank 616 of 3,136

Model Signal

ForecastQ Daily Probabilities

52.8%

36.4%

37.7%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$22.03

Price target$50.67

Implied move+130.0%

Analysts7

ForecastQ Portfolios

TYRA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.